Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Proteomics Int'l Biomarker Study Closer to Diabetic Kidney Disease CDx Test

Published: Tuesday, April 15, 2014
Last Updated: Monday, April 28, 2014
Bookmark and Share
Company is seeking a commercialisation partner to enter the RUO, LDT or IVD markets.

Proteomics International has completed an important milestone towards the development of a companion diagnostic (CDx) test with the validation of several of its protein biomarkers.

The research team authenticated the panel of biomarkers after taking 508 highly curated disease and control samples. Seven biomarkers were validated at high stringency using the company's proprietary mass spectrometry approach.

The mass spectrometry data was then cross-validated using immunoassays in collaboration with the KTH Royal Institute of Technology, Sweden, and Merck Millipore. A further five biomarkers were validated at high stringency and these are available for out-licensing. The validation was supported by a grant from Commercialisation Australia.

Proteomics International managing director Richard Lipscombe said there was excellent correlation between the new mass spectrometry platform and the traditional gold standard test, essential because antibody assays are more readily accepted by the FDA. "By doing it as a diagnostic and showing that the whole approach works, we set the foundations to create tests for other medical conditions," Dr Lipscombe said.

The next stage of development is to create a test that can determine whether patients will get diabetic kidney disease before they develop the condition. "The Holy Grail is to predict who's going to get sick and who isn't and that's something that will come out of our study later in 2014." Dr Lipscombe said. "But in the short term we want a diagnostic test that is going to provide doctors with a more accurate, robust test."

The International Diabetes Foundation estimates that there are 382 million people living with diabetes and expect the number to rise significantly. Based on current statistics 10 to 15 per cent of all people with diabetes will die from kidney disease.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Startup Seeks More Precise Prostate Cancer Screening
Gregor Diagnostics aims to bring a non-invasive prostate cancer screening test to the market.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos